ONO Pharmaceutical
在场
是其中之一......
ONO Pharmaceutical 是一家在股票代码 4528 (JP) 下上市的公司。
ONO Pharmaceutical 在 2 个国家有直接业务。
涉及ONO Pharmaceutical的并购和融资。
高管
查看带有其 37 名主要高管的组织结构图
ONO Pharmaceutical 搜索最多的简介
- Gyo Sagara, President, Chief Director of Sales, Representative Dir...
- Masao Nomura, Independent Director
- Shusaku Nagae, Independent Director
创建提醒
跟踪 ONO Pharmaceutical 的高管变动
药店
ONO Pharmaceutical 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
ONO Pharmaceutical 的最新新闻稿
- Revisions of Consolidated Financial Forecasts and Introduction of Core Basis in Financial Results | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- Notice on the Recipients of the “Osamu Hayaishi Memorial Scholarship for Study Abroad” of the FY2025 Japanese Biochemical Society | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC) | ONO CORPORATEicon_search_whitei
- Ono Enters into License Agreement for LCB97, an Antibody-Drug Conjugate, and Research Collaboration and License Agreement to generate novel ADC candidates by leveraging ConjuAll™ ADC platform with LigaChem Biosciences | ONO CORPORATEicon_search_whiteicon_
- ONO begins Airing New Commercial “Rising to the challenges of Immuno-Oncology” in Japan | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- Ono and Bristol-Myers Squibb KK Submit Supplemental Application of Opdivo and Yervoy in Combination Treatment in Japan to Expand the Use for Unresectable Advanced or Recurrent Microsatellite Instability-High Colorectal Cancer | ONO CORPORATEicon_search_wh
- Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- View more press releases Close
通过电子邮件
